Riskpilot← Back to searchSign inGet full accessAcetabulum AB
ABActiveOrg 5591917090Tunavägen 23Medical specialists activities · NACE 8622Est. 20190 employees
Revenue 2024
SEK 753K
-22% vs 2023
EBITDA margin
86.7%
-29% vs 2023
Equity ratio
70.7%
Financial strength
Net profit 2024
SEK 530K
-28% vs 2023
| Revenue | SEK 753K | -22% |
| EBITDA | SEK 653K | -29% |
| Net profit | SEK 530K | -28% |
| Total assets | SEK 1,7M | +28% |
| Equity | SEK 1,2M | +40% |
| Employees | 0 | — |
Legal name
Acetabulum AB
Org number
5591917090
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
18 januari 2019
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Aktiebolaget ska bedriva medicinsk konsultverksamhet, friskvård, utbildnings-, föreläsnings- samt översättningstjänster inom medicinområdet, förvaltning av fast och lös egendom samt därmed förenlig verksamhet.
Address
Tunavägen 23
Email
elif.bosemark@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 80 | 968 | 753 |
| Staff expenses | — | — | — | — | — | — |
| EBITDA | — | — | — | 68 | 916 | 653 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | 0 | 0 | 0 | 68 | 916 | 653 |
| Net financials | — | — | — | — | 4 | 13 |
| Profit before tax | 0 | 0 | 0 | 67 | 921 | 666 |
| Tax | −0 | −0 | −0 | −19 | −187 | −136 |
| Net profit | 0 | 0 | 0 | 48 | 734 | 530 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | 50 | 50 | 50 | 151 | 1 287 | 1 651 |
| Equity | 50 | 50 | 50 | 98 | 832 | 1 167 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 0 | 0 | 52 | 455 | 484 |
| Total debt | — | — | — | 52 | 455 | 484 |
EBITDA margin
86.7%
This company
15.8%
Market median
+449% vs market
20192024
Equity ratio
70.7%
This company
38.2%
Market median
+85% vs market
20192024
Return on equity
45.4%
This company
18.4%
Market median
+147% vs market
20192024
Net profit margin
70.4%
This company
8.1%
Market median
+769% vs market
20192024
Asset turnover
0.46×
This company
1.12×
Market median
-59% vs market
20192024
Debt / equity
0.41×
This company
0.62×
Market median
+34% vs market
20192024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AK | Audit | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2022 | — | — | |
| Board of Directors | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Acetabulum AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anders Kenneth Nilsson | Audit | 0 companies |
| Elif Bosemark | Deputy Board Member | 0 companies |
| Per Olof Bosemark | Board of Directors | 0 companies |